The American pharmaceutical and medical technology giant Johnson & Johnson has made an agreement to buy the biomedicine company Intra-Cellular Therapies.
Johnson & Johnson's bid is 132 dollars per share, which means a valuation of Intra-Cellular of around 14.6 billion dollars (approximately 165 billion kronor).
Intra-Cellular specializes in developing treatments for patients with disorders in the central nervous system.
What do you think?